Kate Hermans and Feng Tian
August 17, 2022 07:27 AM EDT
People
R&D

Squeezed by As­traZeneca/Dai­ichi Sankyo, biotech de­vel­op­ing HER2 ADC switch­es CEO, launch­es pipeline re­view

Amber Tong

When Am­brx Bio­phar­ma went pub­lic in the sum­mer of 2021 — join­ing in on the go-go times in biotech — ex­ecs cel­e­brat­ed it as the cul­mi­na­tion of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

A service from the Financial Times